RFK Jr.'s made promises about vaccines. Here's what he's done as health secretary The Department of Health and Human Services under Robert F The Independent UK · Jun 27, 2025
COVID Vaccine Side Effects: FDA Announces Rare Heart-Related Reactions - What You Should Know FDA has updated safety warnings for the Pfizer-BioNTech (Comirnaty) and Moderna (Spikevax) COVID-19 vaccines. International Business Times UK · Jun 27, 2025
RFK Jr. Overhauls CDC Vaccine Panel, Sparking Expert Backlash, Boycott From Top Medical Group Health Secretary Robert F. Kennedy Jr.'s newly reconstituted vaccine advisory panel is facing criticism from medical experts and former federal officials after its first meeting strayed sharply from established scientific review norms. Benzinga · Jun 26, 2025
US experts fear all vaccines at risk as Trump officials target mRNA jabs Administration’s actions signal move away from technology as health agencies see vaccine-related shakeups The Guardian - US · Jun 14, 2025
How Is Moderna’s Stock Performance Compared to Other Biotechnology Stocks? Moderna has significantly underperformed other biotechnology stocks over the past year, and analysts remain cautious on the stock’s prospects. Barchart · Jun 6, 2025
What you need to know about Moderna's new COVID vaccine, just approved by the FDA The shot had previously been approved for everyone 12 and older. Now, there are limits. Fortune · Jun 2, 2025
FDA approves Moderna's new lower-dose COVID-19 vaccine The Food and Drug administration has approved a new COVID-19 vaccine made by Moderna but with limits on who can use it The Independent UK · May 31, 2025
HHS cancels funding for bird flu vaccine development because of RNA concerns The Trump administration said the move signals a ‘shift in federal vaccine funding priorities’ The Independent UK · May 29, 2025
Moderna Loses $700M US Contract for Bird Flu Vaccine Development Moderna loses $700 million U.S. contract to develop bird flu vaccine after government review ends funding. International Business Times · May 29, 2025
Trump administration cancels $766 million Moderna contract to fight pandemic flu The Trump administration has canceled $766 million awarded to drugmaker Moderna Inc. to develop a vaccine against potential pandemic influenza viruses, including H5N1 bird flu The Independent UK · May 29, 2025
FDA panel debates COVID vaccine recipe as questions swirl about fall shots Government vaccine advisers are meeting to decide if the recipe for COVID-19 vaccines needs updating for this fall and winter The Independent UK · May 22, 2025
Moderna Stock Looks Ripe for a Short Squeeze Moderna stock has made single-digit gains in the last month, and high short interest suggests that any bullish news could cause a short squeeze MarketBeat · May 22, 2025
Moderna Is the Largest of Barchart’s Bottom 100 Stocks to Buy—But Size Alone Isn’t a Reason to Invest Moderna is the largest market cap in Barchart’s Bottom 100 Stocks to Buy. On Monday, the vaccine maker moved seven spots to the 86th position. You don’t want to make this list if you are the CEO. Here’s why. Barchart · May 20, 2025
This Moderna leader uses AI to resolve conflict on the executive team—all before it even happens “I think I’m pretty good with people, but it gives me an advantage that I didn’t have before.” Fortune · May 19, 2025
LiveScience · May 19, 2025 2-in-1 COVID-flu vaccine looks promising in trial — but experts say approval may be delayed Late-stage trial data suggest that a new COVID-flu vaccine offers good protection against both infections, but experts expect the shot's approval may be delayed.
Barchart · May 8, 2025 Moderna Stock: Analyst Estimates & Ratings As Moderna has significantly lagged behind the broader market over the past year, Wall Street analysts maintain a cautious outlook on the stock’s prospects.
The Independent UK · May 7, 2025 Moderna study shows immune response in older adults for a combo flu and COVID-19 shot A combination shot for flu and COVID-19 using messenger RNA generated antibodies in a company-funded study
The Conversation · Apr 30, 2025 From COVID to cancer: Why Canada’s RNA vaccine leadership matters more than ever As the world marks World Immunization Week, attention turns once again to the lifesaving power of vaccines.
The Independent UK · Apr 28, 2025 FDA scrutiny of Novavax COVID-19 vaccine sparks uncertainty about other shots There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from Novavax
International Business Times UK · Apr 28, 2025 Moderna Faces Suspension After Offering UK Children £1,500 And Teddy Bears To Join COVID Trials Moderna, known for its COVID-19 vaccines, has been found guilty of 10 breaches of regulatory code after it marketed its booster jab trials towards children.
The Independent UK · Apr 23, 2025 Novavax says its COVID-19 shot is on track for full FDA approval after delay Novavax says its closely watched COVID-19 vaccine is on track for full U.S. approval after additional discussions with the Food and Drug Administration
Barchart · Apr 21, 2025 What to Expect From Moderna's Q1 2025 Earnings Report Moderna is scheduled to report its first-quarter results next month, and analysts expect a single-digit earnings growth.
LiveScience · Apr 11, 2025 What are mRNA vaccines, and how do they work? mRNA vaccines train the immune system in a similar way to traditional vaccines, but they use a different strategy to get there.
Fortune · Apr 2, 2025 Analysts at Trump ally Howard Lutnick’s former firm call RFK Jr. ‘an anti-vax, conspiracy theorist with inadequate training’ RFK Jr. was reportedly behind the ouster of FDA’s top vaccine official and said last week that around 10,000 employees will be laid off at the Department of Health and Human Services.
Fortune · Mar 31, 2025 Moderna and Novavax shares plunge after key FDA official steps down, citing discord with RFK Jr. who he says 'wishes subservient confirmation of his misinformation and lies' Massive cuts to personnel and funding within the Department of Health and Human Services presents a headache for vaccine approval and development, analysts say.